Knowing stock market today at a glance

IDEAYA Biosciences Soars 11.27% on FDA Trial Approval

Mover TrackerWednesday, May 7, 2025 5:09 am ET

1min read

On May 7, 2025, IDEAYA Biosciences saw a significant rise of 11.27% in pre-market trading, reflecting strong investor interest and confidence in the company's recent developments.

IDEAYA Biosciences, a precision medicine oncology company, has been actively engaged in the discovery and development of targeted therapeutics for specific patient populations. The company's commitment to precision medicine has been a driving force behind its recent advancements.

Oppenheimer recently lowered its price target for IDEAYA Biosciences from $40 to $37, while maintaining an Outperform rating. This adjustment suggests a cautious optimism about the company's future prospects, despite the reduction in the target price.

IDEAYA Biosciences has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for IDE849, a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC) program. This approval is a significant milestone for the company, as it allows for the evaluation of IDE849 in solid tumors, including small cell lung cancer (SCLC), neuroendocrine tumors (NETs), and non-small cell lung cancer (NSCLC).

The ongoing Phase 1 clinical trial for IDE849 has shown promising results, with multiple partial responses observed and predominantly Grade 1 or 2 treatment-related adverse events. The trial is ongoing, with no reported drug-related discontinuations and the maximum tolerated dose yet to be reached. Hengrui Pharma, the company conducting the trial, plans to present clinical efficacy and safety data at a medical conference in the third quarter of 2025.

In addition to IDE849, IDEAYA is also targeting to present preclinical combination mechanism and synergy efficacy data of IDE161/PARG with TOP1-payload based ADCs at a medical conference in the third quarter of 2025. This potential first-in-class combination has the potential to enhance the durability of IDEAYA's TOP1-payload based ADC pipeline, including IDE849 and IDE034 (B7H3/PTK7 Bispecific TOP1 ADC).

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.